These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17408861)

  • 1. The effect of anticoagulants on cancer risk and survival: systematic review.
    Tagalakis V; Blostein M; Robinson-Cohen C; Kahn SR
    Cancer Treat Rev; 2007 Jun; 33(4):358-68. PubMed ID: 17408861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does antithrombotic therapy improve survival in cancer patients?
    Cunningham MS; Preston RJ; O'Donnell JS
    Blood Rev; 2009 May; 23(3):129-35. PubMed ID: 19046797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.
    Kuderer NM; Khorana AA; Lyman GH; Francis CW
    Cancer; 2007 Sep; 110(5):1149-61. PubMed ID: 17634948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
    Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor and antimetastatic effect of warfarin and heparins.
    Bobek V; Kovarík J
    Biomed Pharmacother; 2004 May; 58(4):213-9. PubMed ID: 15183845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
    Caine GJ; Lip GY
    Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical studies with anticoagulants to improve survival in cancer patients.
    Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
    Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of catheter-related thrombosis in cancer patients.
    Prandoni P
    Lancet; 2009 Feb; 373(9663):523-4. PubMed ID: 19217973
    [No Abstract]   [Full Text] [Related]  

  • 11. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials.
    Carrier M; Tay J; Fergusson D; Wells PS
    J Thromb Haemost; 2007 Dec; 5(12):2552-4. PubMed ID: 18034768
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of venous thromboembolism in cancer patients.
    Kakkar AK; Williamson RC
    Semin Thromb Hemost; 1999; 25(2):239-43. PubMed ID: 10357091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Koppenhagen K; Kirchhof B; Weber U; Bergemann R
    Haemostasis; 1997; 27(2):75-84. PubMed ID: 9212355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin versus low-molecular-weight heparin therapy in cancer patients.
    Zacharski LR; Prandoni P; Monreal M
    Oncologist; 2005 Jan; 10(1):72-9. PubMed ID: 15632254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials.
    Lazo-Langner A; Goss GD; Spaans JN; Rodger MA
    J Thromb Haemost; 2007 Apr; 5(4):729-37. PubMed ID: 17408406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials: reply.
    Sanford D; Lazo-Langner A
    J Thromb Haemost; 2014 Sep; 12(9):1574-5. PubMed ID: 25039759
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials: comment.
    Tardy B; Chalayer E; Chapelle C; Mismetti P
    J Thromb Haemost; 2014 Sep; 12(9):1572-3. PubMed ID: 24976020
    [No Abstract]   [Full Text] [Related]  

  • 20. International normalized ratio and anticoagulation.
    Theerman MR
    Arch Intern Med; 2003 May; 163(10):1242-3; author reply 1244. PubMed ID: 12767971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.